



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/195, 31/28, 31/675, 33/32, 31/44</b> <b>// (A61K 31/195, 31:00) (A61K 31/28,</b> <b>31:00) (A61K 31/675, 31:00) (A61K</b> <b>33/32, 31:00) (A61K 31/44, 31:00)</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/49390</b>  <b>(43) International Publication Date:</b> 31 December 1997 (31.12.97)
<b>(21) International Application Number:</b> PCT/GB97/01721  <b>(22) International Filing Date:</b> 24 June 1997 (24.06.97)  <b>(30) Priority Data:</b> 9613182.6                      24 June 1996 (24.06.96) <b>GB</b>  <b>(71) Applicant (for all designated States except US):</b> NYCOMED IMAGING AS [NO/NO]; Nycoveien 2, N-0401 Oslo (NO).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> TOWART, Robertson [GB/GB]; 13 Sefton Paddock, Stoke Poges SL2 4PT (GB). KARLSSON, Jan, Olof, Gustav [SE/NO]; Solstua Terrasse 4, N-1450 Nesoddtangen (NO). JYNGE, Per [NO/NO]; Erling Skakkesgt 54, N-7013 Trondheim (NO).  <b>(74) Agents:</b> GOLDING, Louise et al.; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
<b>(54) Title:</b> REDUCTION OF CARDIOTOXICITY OF AN ANTITUMOR AGENT USING MANGANESE COMPOUND  <b>(57) Abstract</b>  The invention relates to the use of certain chelating agents and their metal chelates and to the use of certain manganese containing compounds, in particular manganese chelates, in the manufacture of a therapeutic agent for use in reducing the cardiotoxicity of an antitumor agent. Such compounds are particularly effective in reducing the side-effects of anthracycline drugs and/or paclitaxel.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**REDUCTION OF CARDIOTOXICITY OF AN ANTITUMOR AGENT USING MANGANESE COMPOUND**

The present invention relates to the use of chelating agents and their metal chelates and to the use of certain manganese containing compounds, in particular manganese chelates, in medicine. In particular, the invention relates to the use of such compounds in anti-tumour therapy.

A number of anti-tumor agents are associated with adverse side-effects which severely limit their widespread use. Paclitaxel or taxol is one such agent which has shown anti-neoplastic action against a variety of malignant tissues, including those of the breast, colon, lung and ovary as well as in malignant melanoma. However, at the high dosages required to have an anti-neoplastic effect, paclitaxel has a number of adverse side-effects which can include cardiovascular irregularities as well as hematological and gastrointestinal toxicity.

Anthracycline antibiotics, such as doxorubicin (adriamycin), are amongst the most important of the anti-tumour agents. However, their clinical value is limited by their cardiotoxicity, which manifests itself as congestive heart failure in 15-40% of patients undergoing therapy. The most likely mechanism for their toxicity is believed to be the production of oxygen-derived free radicals in the heart, which cause membrane damage and mitochondrial damage in metabolically active tissues such as heart muscle and intestinal mucosa.

There is evidence to suggest that cardiac damage during anthracycline therapy can be reduced by simultaneous administration of the iron chelator, dexrazoxane (Goodman & Gilman, 9th ed. 1233-1287 (1996)). However, dexrazoxane and its analogues have been found to be toxic and as a result can only be used in relatively low dosages.

- 2 -

It will be appreciated that there thus exists a continuing need for compounds which are able to act as chemoprotectants during anti-cancer therapy.

In particular, there exists the need for an effective chemoprotectant which in reducing the toxic side effects of the anti-tumour agent, will permit higher, more effective doses of the anti-tumour agent to be administered.

The medical use of chelating agents and their metal chelates is well established, for example in diagnostic techniques such as X-ray, magnetic resonance imaging (MRI), ultrasound imaging or scintigraphy. A wide variety of chelating agents and metal chelates are known or have been described.

Aminopoly (carboxylic acid or carboxylic acid derivative) chelating agents and their metal chelates are well known and are described for example in EP-A-299795, EP-A-71564, DE-A-3401052, EP-A-203962 and EP-A-436579.

Dipyridoxyl based chelating agents and their chelates with trivalent metals have been described by Taliaferro (Inorg. Chem. 23: 1183-1192 (1984)). The compound N,N'-dipyridoxyl ethylenediamine-N,N'-diacetic acid (PLED) has been evaluated as a chelating agent for the preparation of gallium or indium containing radiopharmaceuticals (see Green et al. Int. J. Nucl. Med. Biol, 12(5): 381-386 (1985)).

A number of PLED derivatives and analogues have also been described for use in MRI contrast media, in particular the chelating agent N,N'-bis-(pyridoxal-5-phosphate)-ethylenediamine-N,N'-diacetic acid (DPDP) and its manganese (II) chelate, Mn DPDP (see EP-A-290047 and EP-A-292761).

We have now found that certain chelating agents, in particular dipyridoxyl and aminopolycarboxylic acid based chelating agents, and their metal chelates are particularly effective in reducing the toxicity of anti-

- 3 -

tumour agents, in particular anthracyclines and paclitaxel.


We have also found that certain manganese containing compounds are effective in reducing the toxicity of anti-tumor agents.

In one aspect the invention provides the use of a physiologically tolerable manganese compound or salt thereof, preferably having a molecular weight of less than 5000, more preferably less than 1000, e.g. less than 800, in the manufacture of a therapeutic agent for use in reducing the cardiotoxicity of an anti-tumour agent, e.g. an anthracycline drug and/or paclitaxel.

In another aspect the invention provides a method of reducing the cardiotoxicity of an anti-tumor agent administered to the human or non-human animal body, said method comprising administering to said body an anti-tumor agent and simultaneously, separately or sequentially a physiologically tolerable manganese compound or salt thereof, preferably having a molecular weight of less than 5000, more preferably less than 1000, e.g. less than 800.

Conveniently, the manganese compound may be present as a chelate, preferably having a  $K_a$  in the range of from  $10^9$  to  $10^{25}$ , more preferably  $10^{10}$  to  $10^{24}$ , yet more preferably  $10^{11}$  to  $10^{23}$ , e.g.  $10^{12}$  to  $10^{22}$ . Particularly preferred chelates are those having a  $K_a$  value smaller by a factor of at least  $10^3$  than the  $K_a$  value of the corresponding iron ( $Fe^{3+}$ ) chelate.

In a second aspect the invention provides the use of a compound of formula I



- 4 -

or a metal chelate or salt thereof in the manufacture of a therapeutic agent for use in reducing the cardiotoxicity of an anti-tumor agent, e.g. an anthracycline and/or paclitaxel

(wherein in formula I

each  $R^1$  independently represents hydrogen or  $-\text{CH}_2\text{COR}^5$ ;

$R^5$  represents hydroxy, optionally hydroxylated alkoxy, amino or alkylamido;

each  $R^2$  independently represents a group  $\text{XYR}^6$ ;  
X represents a bond, or a  $\text{C}_{1-3}$  alkylene or oxoalkylene group optionally substituted by a group  $R^7$ ;

Y represents a bond, an oxygen atom or a group  $\text{NR}^6$ ;

$R^6$  is a hydrogen atom, a group  $\text{COOR}^8$ , an alkyl, alkenyl, cycloalkyl, aryl or aralkyl group optionally substituted by one or more groups selected from  $\text{COOR}^8$ ,  $\text{CONR}^8_2$ ,  $\text{NR}^8_2$ ,  $\text{OR}^8$ ,  $=\text{NR}^8$ ,  $=\text{O}$ ,  $\text{OP}(\text{O})(\text{OR}^8)\text{R}^7$  and  $\text{OSO}_3\text{M}$ ;

$R^7$  is hydroxy, an optionally hydroxylated, optionally alkoxyated alkyl or aminoalkyl group;

$R^8$  is a hydrogen atom or an optionally hydroxylated, optionally alkoxyated alkyl group;

M is a hydrogen atom or one equivalent of a physiologically tolerable cation, e.g. an alkali or alkaline earth cation, an ammonium ion or an organic amine cation, such as a meglumine ion;

$R^3$  represents a  $\text{C}_{1-8}$  alkylene group, preferably a  $\text{C}_{1-6}$ , e.g. a  $\text{C}_{2-4}$  alkylene group, a 1,2-cycloalkylene group, or a 1,2-arylene group; and

each  $R^4$  independently represents hydrogen or  $\text{C}_{1-3}$  alkyl).

Other chelators suitable for use in the method of the invention include the macrocyclic and more preferably linear or branched aminopolycarboxylic acid chelants of EP-A-299795, EP-A-71564, DE-A-3401052, EP-A-203962, EP-A-436579 and the phosphorus oxyacid analogs. Preferred chelating agents include DTPA and EDTA and amides thereof in which the nitrogens of the amide

- 5 -

groups may be substituted by one or more  $C_{1-18}$  alkyl groups, e.g. DTPA.BMA and EDTA.BMA.

As used herein the terms "alkyl" and "alkylene" include both straight-chained and branched, saturated and unsaturated hydrocarbons. The term "1,2-cycloalkylene" includes both cis and trans cycloalkylene groups and alkyl substituted cycloalkylene groups having from 5-8 carbon atoms. The term "1,2-arylene" includes phenyl and naphthyl groups and alkyl substituted derivatives thereof having from 6 to 10 carbon atoms.

Unless otherwise specified, any alkyl, alkylene or alkenyl moiety may conveniently contain from 1 to 20, preferably 1-8, more preferably 1-6 and especially preferably 1-4 carbon atoms.

Cycloalkyl, aryl and aralkyl moieties may conveniently contain 3-18, preferably 5-12 and especially preferably 5-8 ring atoms. Aryl moieties comprising phenyl or naphthyl groups are preferred. As aralkyl groups, phenyl  $C_{1-3}$  alkyl, especially benzyl, are preferred.

Where groups may optionally be substituted by hydroxy groups, this may be monosubstitution or polysubstitution and, in the case of polysubstitution, alkoxy and/or hydroxy substituents may be carried by alkoxy substituents.

In formula I,  $R^5$  is preferably hydroxy,  $C_{1-8}$  alkoxy, ethylene glycol, glycerol, amino or  $C_{1-8}$  alkylamido. Preferably each group  $R^1$  represents  $-CH_2COR^5$  in which  $R^5$  is hydroxy.

In the compounds of formula I, X is preferably a bond or a group selected from  $CH_2$ ,  $(CH_2)_2$ , CO,  $CH_2CO$ ,  $CH_2CH_2CO$  or  $CH_2COCH_2$ . Preferably, Y represents a bond.

The compounds of formula I may have the same or different  $R^2$  groups on the two pyridyl rings and these may be attached at the same or different ring positions. However, it is especially preferred that substitution be at the 5- and 6-positions, most especially the 6-

- 6 -

position, i.e. para to the hydroxy group. Compounds in which the  $R^2$  groups are identical and identically located, e.g. 6,6', are especially preferred.

Preferred as groups  $R^6$  are mono- or poly(hydroxy or alkoxy) alkyl groups or a group of the formula  $OP(O)(OR^8)R^7$ .

$R^7$  is preferably hydroxy or an unsubstituted alkyl or aminoalkyl group.

Particularly preferred identities for group  $R^2$  include  $CHR^7OCO(CH_2)_xPh$  and  $CHR^7OCO(CH_2CO)_xPh$  (wherein  $x$  is 1 to 3),  $CHR^7OCOBu^t$ ,  $CH_2N(H)R^{6'}$ ,  $CH_2N(R^{6'})_2$ ,  $N(H)R^{6'}$ ,  $N(R^{6'})_2$ ,  $CH_2OH$ ,  $CH_2OR^{6'}$ ,  $COOR^{6'}$ ,  $CON(H)R^{6'}$ ,  $CON(R^{6'})_2$  or  $OR^{6'}$  (where  $R^{6'}$  is a mono- or polyhydroxylated, preferably  $C_{1-4}$ , especially preferably  $C_{1-3}$ , alkyl group),  $(CH_2)_nCOOR^{7'}$  (wherein  $n$  is 1 to 6),  $COOR^{7'}$  (where  $R^{7'}$  is a  $C_{1-4}$  alkyl, preferably  $C_{1-3}$ , especially preferably a methyl group),  $CH_2OSO_3^-M$ ,  $CH_2CH_2COOH$ ,  $CH_2OP(O)(OH)(CH_2)_3NH_2$ ,  $CH_2OP(O)(OH)CH_3$  or  $CH_2OP(O)(OH)_2$  group. Yet more preferably,  $R^2$  represents a group of the formula  $CH_2OP(O)(OH)_2$ .

Compounds of formula I in which  $R^3$  is ethylene and  $R^2$  has any of the identities listed above are particularly preferred.

Preferred metal chelates of the compounds for use in the method of the invention are those in which the metal ions are selected from the alkali and alkaline earth metals and from those metals having an atomic number from 22-31, 42, 44 and 58-70 and more particularly chelates having a  $K_a$  in the range from  $10^9$  to  $10^{25}$ , preferably  $10^{10}$  to  $10^{24}$ , more preferably  $10^{11}$  to  $10^{23}$ , e.g.  $10^{12}$  to  $10^{22}$ . Particularly preferred chelates are those with metals other than iron which have a  $K_a$  value smaller, preferably by a factor of at least  $10^3$ , than the  $K_a$  value of the corresponding iron ( $Fe^{3+}$ ) chelate. Suitable ions include  $Na^+$ ,  $Mn^{2+}$ ,  $Cu^+$ ,  $Cu^{2+}$ ,  $Mg^{2+}$ ,  $Gd^{3+}$ ,  $Ca^{2+}$  and  $Zn^{2+}$ .  $Mn^{2+}$  is especially preferred.

As chelates of aminopolycarboxylic acids, MnDTPA, MnEDTA, Mn DTPA.BMA and Mn EDTA.BMA are particularly



- 7 -

preferred for use in accordance with the invention.

More particularly preferred for use in accordance with the invention is the compound N,N'-bis-(pyridoxal-5-phosphate)-ethylenediamine-N,N'-diacetic acid or N,N'-bis(3-hydroxy-2-methyl-5-phosphonomethyl-4-pyridyl-methyl)-ethylenediamine-N,N'-diacetic acid (hereinafter referred to as DPDP) and the manganese (II) chelate, Mn(DPDP).

If not all of the labile hydrogens of the chelates are substituted by the complexed metal ion, biotolerability and/or solubility of the chelate may be increased by substituting the remaining labile hydrogen atoms with physiologically biocompatible cations of inorganic and/or organic bases or amino acids. Examples of suitable inorganic cations include  $\text{Li}^+$ ,  $\text{K}^+$ ,  $\text{Na}^+$  and especially  $\text{Ca}^{2+}$ . Suitable organic cations include ammonium, substituted ammonium, ethanolamine, diethanolamine, morpholine, glucamine, N,N,-dimethyl glucamine, lysine, arginine or ornithine.

A particularly preferred use of the compounds herein described, in particular the chelating agents and their metal chelates, is as cardio-protective agents and such use extends not only to use in conjunction with drugs having cardiotoxic side effects, but also to the treatment or prevention of pathological conditions in which the heart is at risk. Thus, for example, the compounds in accordance with the invention may be used in the prevention or treatment of the cardiotoxic side effects of anti-tumour drugs, in particular the toxicity of anthracyclines, such as doxorubicin, and the toxicity of paclitaxel. In this regard, the compounds of the invention may be administered as a combined preparation with the anti-tumour drug. Alternatively, they may be administered separately, prior to, during or subsequent to administration of the anti-tumour drug.

As used herein the term "anthracyclines" includes natural and semi-synthetic anthracyclines, e.g.

- 8 -

epirubicin, idarubicin, daunorubicin and, in particular, doxorubicin and salts thereof, as well as synthetic anthracyclines, e.g. mitoxantrone, and salts thereof.

Viewed from a further aspect the invention thus provides a pharmaceutical composition comprising a chelating agent according to the invention or a metal chelate or salt thereof, together with one or more anthracyclines, e.g. doxorubicin, and/or paclitaxel, and at least one pharmaceutically acceptable carrier or excipient.

Viewed from a yet still further aspect the invention provides a pack containing a chelating agent according to the invention or a metal chelate or salt thereof and separately an anthracycline and/or paclitaxel for simultaneous, separate or sequential use in anti-tumour therapy.

In another aspect the invention provides the use of a chelating agent according to the invention or a metal chelate or salt thereof together with one or more anthracyclines and/or paclitaxel in the manufacture of medicaments for simultaneous, separate or sequential administration in anti-tumour therapy.

In relation to the use of paclitaxel as the anti-tumor agent, it is preferable that patients are premedicated with steroids, antihistamines and/or H<sub>2</sub>-antagonists to avoid hypersensitivity reactions, in particular anaphylactic reactions. Furthermore, myelotoxicity associated with paclitaxel administration, particularly with high doses of paclitaxel, can be substantially reduced by co-administration of granulocyte-colony stimulating factor (G-CSF), preferably given as a daily injection up to 24 hours after paclitaxel administration.

The compounds of the invention may be prepared by methods known in the art. Suitable methods for preparing the amino polycarboxylic acid based chelating agents are described in EP-A-299795, EP-A-71564, DE-A-

- 9 -

3401052, EP-A-203962 and EP-A-436579.


In preparing the dipyridoxyl compounds, the compound PLED may be used as a starting material and may be appropriately derivatised using conventional procedures to obtain the compounds of formula I.

Suitable methods for preparing the compounds of formula I are described for example in EP-A-290047.

Alternatively the compounds of formula I may be prepared by reacting the corresponding pyridoxal compound with an alkylene diamine according to the procedure for making PLED described by Taliaferro (supra).

Alternatively, the compounds in accordance with the invention may be prepared by a process comprising one or more of the following steps:

(a) reacting a compound of formula II




with a diamine of formula (III)



(wherein  $\text{R}^3$  and  $\text{R}^4$  are as hereinbefore defined and  $\text{R}^{2'}$  is an optionally protected group  $\text{R}^2$  as hereinbefore defined)

(b) hydrogenating a compound of formula (IV) obtained in step (a)


- 10 -



(IV)

(wherein  $R^3$ ,  $R^4$  and  $R^{2'}$  are as hereinbefore defined)

(c) reacting a compound of formula (V)



(V)

(wherein  $R^3$ ,  $R^4$  and  $R^{2'}$  are as hereinbefore defined) with a haloacetic, preferably bromoacetic, acid, and if necessary removing any protecting groups used; and

(d) converting a compound of formula I into a chelate complex or salt thereof.

Pyridoxyl phosphate, pyridoxal and the other compounds of formula II and the alkylene diamine, cycloalkylene diamine and arylene compounds of formula III are well-known compounds readily available or can be readily synthesised by procedures well known in the art.

The reaction of step (a) may conveniently be performed in a suitable solvent, such as an alcohol (e.g. methanol) at a temperature in the range of from 0 to 60°C.

To obtain compounds of formula I where the  $R^2$  groups are the same, a diamine of formula III may be reacted

- 11 -

with two molar equivalents of a compound of formula II. For the preparation of compounds of formula I where the  $R^2$  groups are different, the diamine of formula III is first reacted with a first compound of a formula II having a desired  $R^{2'}$  group, and the reaction product thereby obtained is then reacted with a second compound of formula II bearing a different  $R^{2'}$  group.

The hydrogenation of step (b) may be performed using conventional procedures, e.g. using a palladium or platinum catalyst.

The metal chelates for use in accordance with the invention may be formed by conventional procedures known in the art. In general, such processes involve dissolving or suspending a metal oxide or metal salt (e.g. nitrate, chloride or sulfate) in water or a lower alcohol such as methanol, ethanol, or isopropanol. To this solution or suspension is added an equimolar amount of the chelating agent in water or a lower alcohol and the mixture is stirred, if necessary with heating moderately or to the boiling point, until the reaction is completed. If the chelate salt formed is insoluble in the solvent used, the reaction product is isolated by filtering. If it is soluble, the reaction product is isolated by evaporating to dryness, e.g. by spray drying or lyophilising.

If acid groups such as the phosphoric acid groups are still present in the resulting chelate, it is advantageous to convert the acidic chelate salt into a neutral chelate salt by reaction with inorganic and/or organic bases or amino acids, which form physiologically acceptable cations, and to isolate them.

The carboxylic and phosphoric acid groups of the chelating agents can also be neutralised by esterification to prepare carboxylate and phosphate esters. Such esters can be prepared from the corresponding alcohols by conventional procedures known in the art. Suitable esters include, for example, esters of straight-chained or branched alcohols having

- 12 -

from 1 to 18 carbon atoms, mono and polyhydric alkyl amino alcohols having from 1 to 18 carbon atoms, preferably having from 1 to 6 carbons, such as serinol or diethanolamine, and polyhydric alcohols having from 1 to 18 carbon atoms, such as ethylene glycol or glycerol.

Where the metal chelate carries an overall charge it will conveniently be used in the form of a salt with a physiologically acceptable counterion, for example an ammonium, substituted ammonium, alkali metal or alkaline earth metal (e.g. calcium) cation or an anion deriving from an inorganic or organic acid. In this regard, meglumine salts are particularly preferred.

The therapeutic agents of the present invention may be formulated with conventional pharmaceutical or veterinary formulation aids, for example stabilizers, antioxidants, osmolality adjusting agents, buffers, pH adjusting agents, etc. and may be in a form suitable for parenteral or enteral administration, for example injection or infusion or administration directly into a body cavity having an external escape duct, for example the gastrointestinal tract, the bladder or the uterus. Thus the agent of the present invention may be in a conventional pharmaceutical administration form such as a tablet, capsule, powder, solution, suspension, dispersion, syrup, suppository, etc. However, solutions, suspensions and dispersions in physiologically acceptable carrier media, for example water for injections, will generally be preferred.

The compounds according to the invention may therefore be formulated for administration using physiologically acceptable carriers or excipients in a manner well-known to those skilled in the art. For example, the compounds, optionally with the addition of pharmaceutically acceptable excipients, may be suspended or dissolved in an aqueous medium, with the resulting solution or suspension then being sterilized. Suitable additives include, for example, physiologically biocompatible buffers (e.g. tromethamine hydrochloride),

- 13 -

additions (e.g. 0.01 to 10 mole percent) of chelants (such as, for example, DTPA, DTPA-bisamide or non-complexed chelants of formula I) or calcium chelate complexes (e.g. calcium DTPA, CaNaDTPA-bisamide, calcium salts or chelates of chelants of formula I), or, optionally, additions (e.g. 1 to 50 mole percent) of calcium or sodium salts (e.g. calcium chloride, calcium ascorbate, calcium gluconate or calcium lactate combined with metal chelate complexes of chelating agents according to the invention and the like).

If the compounds are to be formulated in suspension form, e.g., in water or physiological saline for oral administration, a small amount of soluble chelate may be mixed with one or more of the inactive ingredients traditionally present in oral solutions and/or surfactants and/or aromatics for flavouring.

The preferred mode for administering the metal chelates in accordance with the invention is parenteral, e.g. intravenous administration. Parenterally administrable forms, e.g. intravenous solutions, should be sterile and free from physiologically unacceptable agents, and should have low osmolality to minimize irritation or other adverse effects upon administration, and thus the compositions should preferably be isotonic or slightly hypertonic. Suitable vehicles include aqueous vehicles customarily used for administering parenteral solutions such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection and other solutions such as are described in Remington's Pharmaceutical Sciences, 15th ed., Easton: Mack Publishing Co., pp. 1405-1412 and 1461-1487 (1975) and The National Formulary XIV, 14th ed. Washington: American Pharmaceutical Association (1975). The solutions may contain preservatives, antimicrobial agents, buffers and antioxidants conventionally used for parenteral solutions, excipients and other additives which are compatible with the chelates and which will

- 14 -

not interfere with the manufacture, storage or use of the products.

The therapeutic agent in accordance with the invention, if in solution, suspension or dispersion form, will generally contain the chelant or metal chelate at a concentration in the range of from 0.0001 to 5.0 moles per litre, preferably 0.01 to 0.1 moles per litre. If convenient, the therapeutic agent may however be supplied in a more concentrated form for dilution prior to administration.

The therapeutic agent in accordance with the invention may conveniently be administered in amounts of from  $10^{-2}$  to 100  $\mu\text{mol}$  of the compounds per kilogram of body weight, e.g. about 10  $\mu\text{mol}$  per kg bodyweight.

The present invention will now be illustrated further by the following non-limiting Examples and with reference to the attached figures, in which:

Figures 1-4 illustrate the effect of Doxorubicin on the contractile force of the mouse heart muscle following pre-treatment with MnDPDP.

Figure 5 illustrates the effect of Doxorubicin on the contractile force of the mouse heart muscle following pre-treatment with MnPLED.

Figure 6 illustrates the effect of Daunomycin on the contractile force of the mouse heart muscle following pre-treatment with MnDPDP.

#### Example 1

The protective effects of dexrazoxane, manganese chloride, DPDP, MnDPDP and ZnDPDP against doxorubicin were tested in the mouse left atrium model.

#### Method:

Male mice were killed, the left atrium carefully dissected out, and hung in an organ bath filled with 37°C Krebs Henseleit solution. Contractility was measured with a force transducer as described by van Acker et al. (Phlebology Suppl. 1: 31-32 (1993)). After



- 15 -

equilibration, the atrium was preincubated with saline or various concentrations of MnDPDP for 30 minutes. Saline or 120  $\mu$ M doxorubicin was subsequently added and the contractility measured for 60 minutes. Thereafter isoprenaline was added to test the capacity for positive inotropic action.

In another series of experiments male mice were injected intravenously with various doses of saline, dexrazoxane, manganese chloride, MnDPDP, ZnDPDP and DPDP. Fifteen or 30 minutes later the mice were killed and the *in vitro* part of the experiments was conducted as described above.

#### Results:

Typical results are shown in Figures 1-4 attached hereto, and tabulated in Tables 1 and 2 below.

It can be seen that untreated controls (saline addition) contract to almost 100% of original force during the 60 minute measurement period, whereas the atria treated with doxorubicin display a marked negative inotropic effect, presumably due to the damage to isolated atrial muscle, leading to approx. 60% reduction in contractile force within 60 minutes.

It is clear from Figures 1-3 that the manganese compound MnDPDP, when added directly into the organ bath, does not protect the heart muscle from deleterious effects of doxorubicin. However, it is clear from Figure 4 that MnDPDP, when injected into the animal before the heart muscle is removed and placed in the organ bath, unexpectedly protects the heart muscle from the deleterious effects of doxorubicin. From Tables 1 and 2 it can be seen that either 15 or 30 minute pretreatment of the animal produces a 40-48% protection of the contractility. Equimolar doses of either manganese (as the chloride) or DPDP alone, although less effective still provide a degree of protection of the atrial muscle. The Zinc complex ZnDPDP also produced

- 16 -

protective effects.

The reference compound dexrazoxane also protected against doxorubicin-induced cardiotoxicity in this test, although the quantities required were much larger (25-50 mg/kg dexrazoxane = 93-186  $\mu$ mole/kg) compared to the effective doses of MnDPDP (1-10  $\mu$ mole/kg).

**Table 1**

**Protective effects of compounds against  
Doxorubicin-induced Cardiotoxicity**

Compounds injected 15 minutes before removal of cardiac tissue

Compound Tested	% protection*
Saline control	0
1 $\mu$ mole/kg MnDPDP	16
10 $\mu$ mole/kg MnDPDP	40
30 $\mu$ mole/kg MnDPDP	4
100 $\mu$ mole/kg MnDPDP	0

\* % protection is defined as % elevation of contractile force when compared to doxorubicin + saline control.

**Table 2**

**Protective effects of compounds against  
Doxorubicin-induced Cardiotoxicity**

Compounds injected 30 minutes before removal of cardiac tissue

Compound Tested	% protection*
Saline control	0
1 $\mu$ mole/kg MnDPDP	35
10 $\mu$ mole/kg MnDPDP	48

- 17 -

30 $\mu$ mole/kg MnDPDP	2
1 $\mu$ mole/kg DPDP	6
10 $\mu$ mole/kg DPDP	15
30 $\mu$ mole/kg DPDP	10
1 $\mu$ mole/kg ZnDPDP	23
10 $\mu$ mole/kg ZnDPDP	33
30 $\mu$ mole/kg ZnDPDP	6
1 $\mu$ mole/kg MnCl <sub>2</sub>	17
10 $\mu$ mole/kg MnCl <sub>2</sub>	21
30 $\mu$ mole/kg MnCl <sub>2</sub>	28
25 mg/kg dexrazoxane	43
50 mg/kg dexrazoxane	47
100 mg/kg dexrazoxane	0

\* % protection is defined as % elevation of contractile force when compared to doxorubicin + saline control.

### Example 2

The protective effects of saline, MnPLED, MnEDTA, MnDTPA.BMA, MnDTPA, EDTA and DTPA against doxorubicin were tested in another set of experiments.

### Method:

Male mice were injected intravenously with saline, 0.1  $\mu$ mol/kg MnPLED, 10  $\mu$ mol/kg MnEDTA, 10  $\mu$ mol/kg MnDTPA.BMA, 10  $\mu$ mol/kg MnDTPA, 10  $\mu$ mol/kg EDTA or 10  $\mu$ mol/kg DTPA.

Thirty minutes later the mice were killed, the left atrium carefully dissected out, and hung in an organ bath filled with 37°C Krebs Henseleit solution. Contractility was measured as described in Example 1. After equilibration, saline or 60  $\mu$ M doxorubicin was added and the contractility measured for 60 minutes.

- 18 -

Results:

Typical results are shown in Figure 5 attached hereto, and tabulated in Table 3 below.

It can be seen that atria treated with doxorubicin display a marked negative inotropic effect, presumably due to the damage to isolated atrial muscle, leading to approx. 60% reduction in contractile force within 60 minutes.

It is clear from Figure 5 that 0.1  $\mu\text{mol/kg}$  MnPLED, when injected into the animal before the heart muscle is removed and placed in the organ bath, protects the heart muscle from the deleterious effects of doxorubicin. From Table 3 it can be seen that 30 minute pretreatment with 0.1  $\mu\text{mol/kg}$  MnPLED produces 56% protection of the atrial muscle, i.e. MnPLED is a ca. 100-fold more potent protector than MnDPDP (see Example 1). Pre-treatment with MnEDTA, MnDTPA, MnDTPA.BMA, EDTA and DTPA provide 42, 100, 12, 9 and 0% protection respectively. Whereas most of the tested manganese compounds gave effective protection, it is clear that equimolar doses of either EDTA or DTPA alone gave little or no protection.

Table 3

Protective effects of compounds against  
Doxorubicin-induced Cardiotoxicity

Compounds injected 30 minutes before removal of cardiac tissue

Compound Tested	% Protection*
Saline control	0 (n=7)
0.1 $\mu\text{mol/kg}$ MnPLED	56 (n=3)
10 $\mu\text{mol/kg}$ MnEDTA	42 (n=6)

- 19 -

10 $\mu$ mol/kg MnDTPA	100 (n=3)
10 $\mu$ mol/kg MnDTPA.BMA	12 (n=3)
10 $\mu$ mol/kg EDTA	9 (n=5)
10 $\mu$ mol/kg DTPA	0 (n=3)

\* % protection is defined as % elevation of contractile force when compared to doxorubicin + saline control.

### Example 3

The protective effect of MnDPDP against daunomycin was tested in the mouse left atrium model.

#### Method:

Male mice were injected intravenously with saline or 10  $\mu$ mol/kg MnDPDP.

Thirty minutes later the mice were killed, the left atrium carefully dissected out, and hung in an organ bath filled with 37°C Krebs Henseleit solution. Contractility was measured as described in Example 1. After equilibration, saline or 60  $\mu$ mol/kg daunomycin was added to the organ bath and the contractility was measured for 60 minutes. Isoprenalin was added subsequently to test the tissue capacity for positive inotropic action.

#### Results:


The results are shown in Figure 6 attached hereto.

It can be seen that the untreated control (saline addition) contracted to almost 100% of original force during the 60 minute measurement period, whereas the muscles treated with daunomycin showed negative inotropic effects, leading to approx. 40% reduction of contractile force within 60 minutes. Pretreatment with 10  $\mu$ mol/kg MnDPDP resulted in approx. 100% protection.

- 20 -

Claims:

1. Use of a physiologically tolerable manganese compound or salt thereof in the manufacture of a therapeutic agent for use in reducing the cardiotoxicity of an anti-tumor agent.
2. Use as claimed in claim 1 wherein said therapeutic agent is for use in conjunction with an anthracycline drug and/or paclitaxel.
3. Use as claimed in claim 2 wherein said anthracycline drug is doxorubicin or daunomycin.
4. Use as claimed in any one of claims 1 to 3 wherein said manganese compound is a manganese chelate.
5. Use as claimed in claim 4 wherein said chelate has a  $K_a$  in the range of from  $10^9$  to  $10^{25}$ .
6. Use as claimed in claim 4 wherein said chelate has a  $K_a$  in the range of from  $10^{12}$  to  $10^{22}$ .
7. Use as claimed in claim 4 wherein said chelate has a  $K_a$  value smaller by a factor of at least  $10^3$  than the  $K_a$  value of the corresponding iron ( $Fe^{3+}$ ) chelate.
8. Use as claimed in claim 4 wherein said manganese chelate comprises a chelating compound of formula I:



(I)

- 21 -

or a salt thereof

(wherein in formula I

each  $R^1$  independently represents hydrogen or  $-\text{CH}_2\text{COR}^5$ ;

$R^5$  represents hydroxy, optionally hydroxylated alkoxy, amino or alkylamido;

each  $R^2$  independently represents a group  $\text{XYR}^6$ ;

X represents a bond, or a  $\text{C}_{1-3}$  alkylene or oxoalkylene group optionally substituted by a group  $R^7$ ;

Y represents a bond, an oxygen atom or a group  $\text{NR}^6$ ;

$R^6$  is a hydrogen atom, a group  $\text{COOR}^8$ , an alkyl, alkenyl, cycloalkyl, aryl or aralkyl group optionally substituted by one or more groups selected from  $\text{COOR}^8$ ,  $\text{CONR}^8$ ,  $\text{NR}^8$ ,  $\text{OR}^8$ ,  $=\text{NR}^8$ ,  $=\text{O}$ ,  $\text{OP}(\text{O})(\text{OR}^8)\text{R}^7$  and  $\text{OSO}_3\text{M}$ ;

$R^7$  is hydroxy, an optionally hydroxylated, optionally alkoxyated alkyl or aminoalkyl group;

$R^8$  is a hydrogen atom or an optionally hydroxylated, optionally alkoxyated alkyl group;

M is a hydrogen atom or one equivalent of a physiologically tolerable cation;

$R^3$  represents a  $\text{C}_{1-8}$  alkylene group, a 1,2-cycloalkylene group, or a 1,2-arylene group; and

each  $R^4$  independently represents hydrogen or  $\text{C}_{1-3}$  alkyl).

9. Use as claimed in claim 8 wherein in formula I:

$R^5$  is hydroxy,  $\text{C}_{1-8}$  alkoxy, ethylene glycol, glycerol, amino or  $\text{C}_{1-8}$  alkylamido;

X is a bond or a group selected from  $\text{CH}_2$ ,  $(\text{CH}_2)_2$ ,  $\text{CO}$ ,  $\text{CH}_2\text{CO}$ ,  $\text{CH}_2\text{CH}_2\text{CO}$  or  $\text{CH}_2\text{COCH}_2$ ;

Y is a bond;

$R^6$  is a mono- or poly(hydroxy or alkoxyated) alkyl group or a group of the formula  $\text{OP}(\text{O})(\text{OR}^8)\text{R}^7$ ; and

$R^7$  is hydroxy, or an unsubstituted alkyl or aminoalkyl group.

10. Use as claimed in claim 8 or claim 9 wherein in formula I,  $R^3$  is ethylene and each group  $R^1$  represents

- 22 -


$-\text{CH}_2\text{COR}^5$  in which  $\text{R}^5$  is hydroxy.

11. Use as claimed in any one of claims 8 to 10 in which the compound of formula I is N,N'-bis-(pyridoxal-5-phosphate)-ethylenediamine-N,N'-diacetic acid.

12. Use as claimed in claim 4 wherein said manganese chelate comprises a linear, branched or macrocyclic aminopolycarboxylic acid or derivative thereof.

13. Use as claimed in claim 12 wherein said chelate comprises ethylenediamine tetraacetic acid, diethylenetriamine pentaacetic acid or a derivative thereof.

14. Use of a compound of formula I:



(I)

or a metal chelate or salt thereof in the manufacture of a therapeutic agent for use in reducing the cardiotoxicity of an anti-tumor agent

(wherein in formula I

each  $\text{R}^1$  independently represents hydrogen or  $-\text{CH}_2\text{COR}^5$ ;

$\text{R}^5$  represents hydroxy, optionally hydroxylated alkoxy, amino or alkylamido;

each  $\text{R}^2$  independently represents a group  $\text{XYR}^6$ ;

X represents a bond, or a  $\text{C}_{1-3}$  alkylene or oxoalkylene group optionally substituted by a group  $\text{R}^7$ ;



- 23 -

Y represents a bond, an oxygen atom or a group  $\text{NR}^6$ ;

$\text{R}^6$  is a hydrogen atom, a group  $\text{COOR}^8$ , an alkyl, alkenyl, cycloalkyl, aryl or aralkyl group optionally substituted by one or more groups selected from  $\text{COOR}^8$ ,  $\text{CONR}_2^8$ ,  $\text{NR}_2^8$ ,  $\text{OR}^8$ ,  $=\text{NR}^8$ ,  $=\text{O}$ ,  $\text{OP}(\text{O})(\text{OR}^8)\text{R}^7$  and  $\text{OSO}_3\text{M}$ ;

$\text{R}^7$  is hydroxy, an optionally hydroxylated, optionally alkoxyated alkyl or aminoalkyl group;

$\text{R}^8$  is a hydrogen atom or an optionally hydroxylated, optionally alkoxyated alkyl group;

M is a hydrogen atom or one equivalent of a physiologically tolerable cation;

$\text{R}^3$  represents a  $\text{C}_{1-8}$  alkylene group, a 1,2-cycloalkylene group, or a 1,2-arylene group; and

each  $\text{R}^4$  independently represents hydrogen or  $\text{C}_{1-3}$  alkyl).

15. Use as claimed in claim 14 wherein said metal chelate comprises a metal ion selected from the alkali and alkaline earth metals and metals having an atomic number of from 22-31, 42, 44 and 58-70.

16. Use as claimed in claim 15 wherein said metal ion is selected from  $\text{Na}^+$ ,  $\text{Mn}^{2+}$ ,  $\text{Cu}^+$ ,  $\text{Cu}^{2+}$ ,  $\text{Mg}^{2+}$ ,  $\text{Gd}^{3+}$ ,  $\text{Ca}^{2+}$  and  $\text{Zn}^{2+}$ .

17. Use of a compound as defined in any one of claims 1 to 16 together with at least one anthracycline and/or paclitaxel in the manufacture of medicaments for simultaneous, separate or sequential administration in anti-tumor therapy.

18. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 16, together with at least one anthracycline and/or paclitaxel and at least one pharmaceutically acceptable carrier or excipient.

- 24 -

19. A pack containing a compound as defined in any one of claims 1 to 16, and separately at least one anthracycline and/or paclitaxel for simultaneous, separate or sequential use in anti-tumor therapy.

20. A method of reducing the cardiotoxicity of an anti-tumor agent administered to a human or non-human animal body, said method comprising administering to said body an anti-tumor agent and simultaneously, separately or sequentially a compound as defined in any one of claims 1 to 16.

1/6


ISOLATED LEFT ATRIA MOUSE  
FIELD STIMULATIONCONTRACTILE FORCE  
(MEAN  $\pm$  SEM)

FIG. 1

SUBSTITUTE SHEET (RULE 26)

2 / 6


ISOLATED LEFT ATRIA MOUSE  
FIELD STIMULATIONCONTRACTILE FORCE  
(MEAN + SEM)

FIG. 2

SUBSTITUTE SHEET (RULE 26)

3/6

ISOLATED LEFT ATRIA MOUSE  
FIELD STIMULATIONCONTRACTILE FORCE  
(MEAN + SEM)

- 120  $\mu$ M DOXORUBICIN (n = 10)  
□ 120  $\mu$ M DOXORUBICIN +  $10^{-5}$  mol / l Mn DPDP (n = 2)  
△ NaCl CONTROL (n = 6)




FIG. 3

SUBSTITUTE SHEET (RULE 26)

4/6

ISOLATED LEFT ATRIA MOUSE  
FIELD STIMULATIONCONTRACTILE FORCE  
(MEAN + SEM)

30 MIN BEFORE DOXORUBICIN

- 120  $\mu$ M DOXORUBICIN + NaCl i.v. (n = 9)
- 120  $\mu$ M DOXORUBICIN + 30  $\mu$ M/kg i.v. Mn-DPOP (n = 3)
- △ 120  $\mu$ M DOXORUBICIN + 10  $\mu$ M/kg i.v. Mn-DPOP (n = 3)
- ◇ 120  $\mu$ M DOXORUBICIN + 1  $\mu$ M/kg i.v. Mn-DPOP (n = 3)
- ▽ NaCl CONTROL (n = 4)




FIG. 4

SUBSTITUTE SHEET (RULE 26)

5 / 6





FIG. 5

SUBSTITUTE SHEET (RULE 26)

6/6



SUBSTITUTE SHEET (RULE 26)



## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 97/01721

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 6 A61K31/195 A61K31/28 A61K31/675 A61K33/32 A61K31/44 //(A61K31/195,31:00),(A61K31/28,31:00),(A61K31/675,31:00), (A61K33/32,31:00),(A61K31/44,31:00) According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 6 A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LEE ET AL.: "Adriamycin cardiotoxicity and essential trace metal homeostasis in the in vivo rat heart" DISS. ABST. INT (SCI.), vol. 46, no. 10, 1986, page 3396 XP002043364 see abstract ---	1-3,10, 20
A	CARSWELL: "NMR used to study drug's toxic effects" JAMA, vol. 248, no. 31, 2 July 1982 - 24 December 1982, pages 814-819, XP002043365 see the whole document --- -/--	1-3
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search 13 October 1997		Date of mailing of the international search report 24.10.97
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Gac, G

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 97/01721

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>BRUROK: "Effects of manganese dipyridoxyl diphosphate, dipyridoxyl diphosphate--, and manganese chloride on cardiac function. An experimental study in the Langendorff perfused rat heart"</p> <p>INVEST. RADIOLOG.,</p> <p>vol. 30, no. 3, 1995,</p> <p>pages 159-167, XP002043366</p> <p>see the whole document</p> <p>-----</p>	<p>1,4-11,</p> <p>14-16,20</p>

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB 97/01721

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Remark : Although claim 20  
is directed to a method of treatment of the  
human/animal body , the search has been carried out and based on the  
alleged effects of the compound/composition.